Atlas Trials

A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC

Clinical trial NCT06754644 · RECRUITING

Trial details

NCT number
NCT06754644
Sponsor
Qilu Pharmaceutical Co., Ltd.
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
NSCLC
Start date
2025-01-15
Primary completion
2026-12-01
Enrollment
808

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.